Image_1_Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.TIFF
Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin type-1 domain-containing 7A (THSD7A) in 70 and 3% of patients, respectively. Antibody titer is correlated with disease activity: rising during active disease and decreasing before remission. Therefore, decreasing PLA2R1-Antibodies titer has become an important goal of therapy. Rituximab a chimeric monoclonal antibody induces remission in 60–80% of primary MN patients. All monoclonal antibodies such as rituximab can elicit antidrug antibodies, which may interfere with therapeutic response. We aim to analyze the relevance of anti-rituximab antibodies on the outcome of MN after a first course of rituximab. Forty-four MN patients were included and treated with two 1 g infusions of rituximab at 2-weeks interval. Anti-rituximab antibodies, CD19 count, and clinical response were analyzed. Then, we (i) analyzed the association of anti-rituximab antibodies at month-6 with response to treatment: remission, relapse and the need for another rituximab course; (ii) confirmed if anti-rituximab antibodies could neutralize rituximab B-cells depletion; and (iii) tested whether anti-rituximab antibodies could cross-inhibit new humanized anti-CD20 therapies. Anti-rituximab antibodies were detected in 10 patients (23%). Seventeen patients received a second rituximab course after a median time of 12 months (7–12), following nine cases of resistance and eight relapses. Anti-rituximab antibodies were significantly associated with faster B-cell reconstitution at month-6 (75 [57–89] vs. 2 [0–41] cells/μl, p = 0.006), higher proteinuria 12 months after rituximab infusion (1.7 [0.7; 5.8] vs. 0.6 [0.2; 3.4], p = 0.03) and before treatment modification (3.5 [1.6; 7.1] vs. 1.7 [0.2; 1.7] p = 0.0004). Remission rate 6 months after rituximab was not different according to anti-rituximab status (p > 0.99) but the rate of relapse was significantly higher for patients with anti-rituximab antibodies (p < 0.001). These patients required more frequently a second course of rituximab infusions (7/10 vs. 10/34, p = 0.03). Anti-rituximab antibodies neutralized rituximab activity in 8/10 patients and cross-reacted with other humanized monoclonal antibodies in only two patients. Three patients with anti-rituximab antibodies were successfully treated with ofatumumab. Anti-rituximab antibodies could neutralize rituximab B cells cytotoxicity and impact clinical outcome of MN patients. Humanized anti-CD20 seems to be a satisfying therapeutic alternative for patients with anti-rituximab antibodies and resistant or relapsing MN.
History
References
- https://doi.org//10.1056/NEJMoa0810457
- https://doi.org//10.1056/NEJMoa1409354
- https://doi.org//10.1681/ASN.2010111125
- https://doi.org//10.1056/NEJM199307083290203
- https://doi.org//10.1038/ki.2012.486
- https://doi.org//10.1097/00001813-200112004-00001
- https://doi.org//10.3324/haematol.2008.001628
- https://doi.org//10.1056/NEJMoa0909169
- https://doi.org//10.1056/NEJMoa1404231
- https://doi.org//10.2215/CJN.00570109
- https://doi.org//10.1002/art.22046
- https://doi.org//10.1016/j.clim.2009.05.007
- https://doi.org//10.1002/acr.20419
- https://doi.org//10.1016/S0140-6736(02)11042-7
- https://doi.org//10.1038/sj.ki.5002628
- https://doi.org//10.2215/CJN.05080610
- https://doi.org//10.1681/ASN.2016040449
- https://doi.org//10.1681/ASN.2016091022
- https://doi.org//10.1056/NEJMoa1814427
- https://doi.org//10.2215/CJN.11791018
- https://doi.org//10.1136/ard.2009.109041
- https://doi.org//10.1158/1078-0432.CCR-10-1292
- https://doi.org//10.1093/ndt/gfz041
- https://doi.org//10.1016/j.jim.2017.09.001
- https://doi.org//10.1016/j.leukres.2005.09.008
- https://doi.org//10.1136/annrheumdis-2012-202220
- https://doi.org//10.1056/NEJMoa1614062
- https://doi.org//10.1093/rheumatology/kez430
- https://doi.org//10.1136/annrheumdis-2019-215200
- https://doi.org//10.4172/1948-5956.1000373
- https://doi.org//10.2165/11539590-000000000-00000
- https://doi.org//10.1056/NEJMoa020888
- https://doi.org//10.1136/ard.2006.065615
- https://doi.org//10.1007/s11926-007-0042-x
- https://doi.org//10.1002/art.22214
- https://doi.org//10.1136/ard.2007.083162
- https://doi.org//10.1177/1352458517720044
- https://doi.org//10.1681/ASN.2015050523
- https://doi.org//10.1097/BOR.0b013e328329ed8b
- https://doi.org//10.3389/fimmu.2016.00021
- https://doi.org//10.1111/jdv.12549
- https://doi.org//10.1002/art.21671
- https://doi.org//10.1038/jid.2014.295
- https://doi.org//10.1136/bmjopen-2016-013319
- https://doi.org//10.1038/ki.2014.381
- https://doi.org//10.1681/ASN.2014070640
- https://doi.org//10.1681/ASN.2014111061
- https://doi.org//10.1681/ASN.2017070734
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity